HC Wainwright Reiterates “Buy” Rating for Benitec Biopharma (NASDAQ:BNTC)

HC Wainwright restated their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $28.00 price objective on the biotechnology company’s stock.

Several other research analysts have also weighed in on BNTC. Robert W. Baird began coverage on Benitec Biopharma in a research report on Friday, December 13th. They issued an “outperform” rating and a $30.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $17.00 price objective on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Finally, Baird R W upgraded Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Benitec Biopharma currently has an average rating of “Buy” and an average target price of $24.43.

Benitec Biopharma Trading Down 4.5 %

NASDAQ BNTC opened at $14.01 on Monday. The business’s 50-day moving average price is $12.14 and its 200 day moving average price is $11.07. Benitec Biopharma has a twelve month low of $4.75 and a twelve month high of $16.90. The company has a market capitalization of $328.55 million, a PE ratio of -9.28 and a beta of 0.92.

Benitec Biopharma (NASDAQ:BNTC) last released its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.19. Equities analysts predict that Benitec Biopharma will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Benitec Biopharma

A number of large investors have recently modified their holdings of the stock. Acuta Capital Partners LLC acquired a new position in Benitec Biopharma during the 3rd quarter worth approximately $274,000. Ameriprise Financial Inc. raised its stake in shares of Benitec Biopharma by 138.4% during the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 20,597 shares during the period. 683 Capital Management LLC acquired a new position in shares of Benitec Biopharma during the fourth quarter worth $452,000. Northern Trust Corp boosted its stake in shares of Benitec Biopharma by 54.2% in the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 13,425 shares during the period. Finally, MYDA Advisors LLC acquired a new stake in Benitec Biopharma during the 4th quarter valued at $632,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.